Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)-Reference-Cited by-同舟云学术

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

Published:2019-09 Issue: Volume:119 Page:168-178
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Nathan Paul,Ascierto Paolo A.^ORCID,Haanen John,Espinosa Enrique,Demidov Lev,Garbe Claus,Guida Michele,Lorigan Paul^ORCID,Chiarion-Sileni Vanna,Gogas Helen,Maio Michele,Fierro Maria Teresa,Hoeller Christoph,Terheyden Patrick,Gutzmer Ralf,Guren Tormod K.,Bafaloukos Dimitrios,Rutkowski Piotr^ORCID,Plummer Ruth,Waterston Ashita,Kaatz Martin,Mandala Mario,Marquez-Rodas Ivan,Muñoz-Couselo Eva,Dummer Reinhard,Grigoryeva Elena,Young Tina C.,Schadendorf Dirk^ORCID

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis;D′Angelo;J Clin Oncol,2017

2. Immunotherapy for the treatment of uveal melanoma: current status and emerging therapies;Komatsubara;Curr Oncol Rep,2017

3. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005;Bradford,2009

4. Biology and treatment of BRAF mutant metastatic melanoma;Kong;Melanoma Manag,2016

5. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia;Bastian;Annu Rev Pathol,2014

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Characteristics and Special Considerations in the Management of Rare Melanoma Subtypes;Cancers;2024-06-28

2. Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy;The Oncologist;2024-05-20

3. Vaginal Malignant Melanoma-Case Report and Comprehensive Review of Literature;Indian Journal of Gynecologic Oncology;2024-05-15

4. Project Optimus Elicits the “Holistic” Benefits of PK/PD Modeling of Immunotherapy;Clinical Cancer Research;2024-05-14

5. Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?;Frontiers in Immunology;2024-05-10